

Attorney Docket No. 5390.200-US
Dorwald et al.
Serial No. 09/548,031 Filed April 12, 2000

RESPONSE

The examiner states in the Office Action Summary that claims numbered 102-107, 110-112, 114, 115, 121, 122 and 124-132 are pending in the application; claims numbered 102-105 are rejected; and claims numbered 106, 107, 110-112, 114, 115, 121, 122, and 124-132 are objected to.


(1) The examiner has rejected claims numbered 102-105 under 35 U.S.C. §102(b) as being anticipated by Stocker et al. Chemical Abstracts 112:216653, in particular compound RN 126036-49-5.

Applicant has amended claim number 102 to remove "aryl optionally substituted with C₁₋₆ alkyl" as an option for R³ and R⁴, which Applicant believes obviates the examiner's rejection. Applicant has also removed "phenyl" as an option for R³ in the last proviso of claim 102.

Applicant respectfully requests reconsideration and withdrawal of the rejection under 35 U.S.C. §102(b), and the objection to the claims dependent on the rejected base claim.

Applicant believes the claims are in condition for allowance. The examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Date: December 16, 2004

Rosemarie R. Wilk-Orescan
Registration Number 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE